Elevated VAFs, particularly for JAK2 V617F, are linked to increased hematologic abnormalities and thrombotic risk in PV and ET patients, whereas CALR mutations correlate with distinct disease manifestations and outcomes. This evidence concerns the gene JAK2 and acquired polycythemia vera.